Categories
Change Password!
Reset Password!
Patients with rheumatoid arthritis can have improved
functional disability along with
low disease activity from the use of CT-P13 in subcutaneous formulation.
As per the outcomes of the network
meta-regression techniques published in Arthritis Research & Therapy journal, the use of only EU approved subcutaneous (SC)
formulation of infliximab (CT-P13
SC) displayed higher clinical response rates, low disease activity and
clinically meaningful improvement in functional disability than intravenous (IV)
infliximab formulations
(CT-P13 IV).
The data of total 949 rheumatoid arthritis (RA) patients
from two randomised trials were distinguished to study the efficacy of SC
formulation of infliximab with IV formulation, and; IV formulation of
infliximub with reference IV formulation of infliximab.
Along with disease activity scores, the changes from
starting position in remission rates and clinically significant improvement in
functional disability based on the Health Assessment Questionnaire–Disability
Index (HAQ-DI) were studied.
The pooled data for 840 patients and 751 patients were
assessed at weeks 30 and 54, individually. At 30 weeks, statistically significant
differences were observed in 28-joint Disease Activity Score as per C-reactive
protein (DAS28-CRP); Simplified and Clinical Disease Activity Index ((SDAI and
CDAI) scores supporting the use of CT-P13 SC in RA patients.
These differences remained consistent through weeks 30 to 54
supporting the use of CT-P13 SC. Comparison of SC with IV formulations and
reference infliximab IV revealed similar outcomes.
CT-P13 SC can serve as an useful substitute
to infliximab IV, as deduced.
Arthritis Research & Therapy
Comparative efficacy of subcutaneous (CT-P13) and intravenous infliximab in adult patients with rheumatoid arthritis: a network meta-regression of individual patient data from two randomised trials
Bernard Combe et al.
Comments (0)